Ultragenyx Pharmaceutical (RARE) Lowered to “Sell” at BidaskClub

BidaskClub downgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a sell rating in a research note released on Tuesday morning.

A number of other research firms have also recently commented on RARE. Jefferies Group raised shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating and upped their target price for the company from $58.00 to $72.00 in a research report on Monday, December 4th. Canaccord Genuity set a $80.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a research report on Thursday, November 16th. Cowen reaffirmed a buy rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 15th. JPMorgan Chase & Co. reaffirmed a buy rating and issued a $76.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Sunday, November 5th. Finally, Robert W. Baird reaffirmed a buy rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 19th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $72.06.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up $1.91 during mid-day trading on Tuesday, hitting $49.16. 614,263 shares of the stock traded hands, compared to its average volume of 318,190. The firm has a market cap of $2,012.33, a PE ratio of -7.05 and a beta of 1.83. Ultragenyx Pharmaceutical has a 1 year low of $43.14 and a 1 year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, meeting the consensus estimate of ($1.87). The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. The company’s revenue was up 81.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.64) EPS. sell-side analysts expect that Ultragenyx Pharmaceutical will post -7.31 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in RARE. Schwab Charles Investment Management Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 3.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 219,415 shares of the biopharmaceutical company’s stock worth $13,628,000 after buying an additional 7,618 shares during the period. Legal & General Group Plc increased its stake in shares of Ultragenyx Pharmaceutical by 17.2% during the second quarter. Legal & General Group Plc now owns 15,082 shares of the biopharmaceutical company’s stock worth $933,000 after buying an additional 2,212 shares during the period. Prudential Financial Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 85.0% during the second quarter. Prudential Financial Inc. now owns 6,770 shares of the biopharmaceutical company’s stock worth $420,000 after buying an additional 3,110 shares during the period. Principal Financial Group Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 1.0% during the second quarter. Principal Financial Group Inc. now owns 73,412 shares of the biopharmaceutical company’s stock worth $4,559,000 after buying an additional 722 shares during the period. Finally, Swiss National Bank increased its stake in shares of Ultragenyx Pharmaceutical by 3.3% during the second quarter. Swiss National Bank now owns 66,052 shares of the biopharmaceutical company’s stock worth $4,102,000 after buying an additional 2,100 shares during the period. Hedge funds and other institutional investors own 94.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Ultragenyx Pharmaceutical (RARE) Lowered to “Sell” at BidaskClub” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/20/ultragenyx-pharmaceutical-rare-lowered-to-sell-at-bidaskclub.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply